Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE) is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Established to address the unmet medical needs of patients with serious, life-threatening conditions, the company specializes in innovative treatments targeting underlying genetic causes.
Company News
The article discusses the Vanguard Russell 1000 Growth ETF as an attractive investment option, highlighting its low-cost, diversified approach to tracking large-cap U.S. stocks with strong growth potential.
Ultragenyx Pharmaceutical granted 113,572 restricted stock units to 33 newly hired non-executive officers, with units vesting over four years and subject to continuous employment.
Leerink Partners upgraded Ionis Pharmaceuticals' stock from Market Perform to Outperform, citing the company's focus on wholly-owned assets like olezarsen and donidalorsen, which are nearing commercialization.
14 analysts have provided a mix of bullish and bearish perspectives on Ultragenyx Pharmaceutical, with an average 12-month price target of $86.79 and a range of $45.00 to $127.00. The company's financial metrics, including revenue growth, net margin, and return on equity, are analyzed.
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.